VEGF blockade induces vasoconstriction, which explains why the most common class adverse effect is hypertension, present in 68% of patients taking lenvatinib and 41% taking sorafenib in the SELECT and DECISION phase III trials, respectively.5, 6, 9. This evidence concerns the gene VEGFA and hypertensive disorder.